Background and Date of Approval

Recombinant Human Erythropoietin Alfa or epoietin alfa is a medication used for treating anaemia due to chronic disease conditions. It was approved for its medical use in 1989.

Mechanism of Action of Recombinant Human Erythropoietin Alfa/epoetin Alfa

Epoietin Alfa Injection is a 165 amino acid glycoprotein manufactured using recombinant DNA technology. Its effects are similar to that of erythropoietin synthesized naturally by our bodies. Erythropoietin is a hormone that releases from the kidney when it senses hypoxia or anaemia. Epoietin Alfa Injection binds to certain receptors on the surface of target cells and regulates gene expression. This in turn stimulates bone marrow to increase haemoglobin and RBC levels in the blood.